Register
Community
Overview
Experts
Editors
Fellows
Code of conduct
AI Guidelines for Physicians
Company
About Us
FAQs
Privacy Policy
Terms of Use
Careers
Programs
News
News Releases
Press Coverage
Publications
Blog
Contact Us
Sign in
Please select the option that best describes you:
Topics:
Rheumatology
•
Rheumatoid Arthritis
•
General Rheumatology
How do you approach treatment intensification in patients with RA and low disease activity but not in remission, considering the potential risks of increased immunosuppression?
Related Questions
How do you approach managing nausea and GI side effects when initiating methotrexate?
Can Xolair (omalizumab) be safely used in combination with biologics for patients with rheumatic disease?
What is the maximum dose of leucovorin that you use with methotrexate?
Do you have any experience with compounded iguratimod either as adjunctive therapy or monotherapy for rheumatoid arthritis, Sjogrens, or axial spondyloarthropathy?
How would you manage a patient with hidradenitis suppurativa and inflammatory arthritis (RA vs. PsA)?
What is your approach to differentiating RA-ILD from medication toxicity (I.e. from methotrexate)?
What is your approach to assessing inflammatory arthritis flares in joints that have been replaced (such as knees)?
Are you comfortable trying a different JAK inhibitor in patients with prior JAK inhibitor allergy?
Are you comfortable with using NSAIDs in a patient on methotrexate for inflammatory arthritis?
Can Dupixent (dupliumab) be safely used in patients who are taking other biologics for rheumatic disease?
